Rosacea

• Vascular dysregulation and abnormal vasoreactivity: The primary defect in rosacea involves dysfunction of facial cutaneous blood vessels. Affected individuals demonstrate abnormal vasodilatory responses to various triggers (heat, spicy foods, alcohol, emotional stress), resulting in transient and then persistent facial erythema. This exaggerated vascular response is mediated by enhanced expression of vasodilatory mediators including substance P, calcitonin gene-related peptide (CGRP), and bradykinin. Chronically, repetitive vasodilation leads to progressive vessel dilation and ultimately structural changes including telangiectasia (visible dilated capillaries). The vascular endothelium becomes increasingly reactive, with decreased nitric oxide bioavailability and increased oxidative stress contributing to persistent inflammation.

• Neurogenic inflammation and neuropeptide signaling: Rosacea involves aberrant neuroimmune signaling between sensory nerves and cutaneous immune cells. Elevated levels of neuropeptides, particularly substance P and CGRP, are released from sensory nerve fibers in response to physical and emotional triggers. These neuropeptides act on mast cells and other immune cells to promote degranulation and release of inflammatory mediators (histamine, cytokines, proteases). The trigeminal nerve system is particularly implicated, as rosacea predominantly affects the V1 (ophthalmic) and V2 (maxillary) distributions. This neurogenic component explains the prominent role of environmental triggers and emotional factors in disease exacerbation.

• Innate immune activation and Demodex mite hypothesis: Dysregulation of innate immunity with enhanced Toll-like receptor (TLR) signaling—particularly TLR2 and TLR4—drives sustained inflammation in rosacea. The elevation of serine protease kallikrein-5 (KLK5) in rosacea skin increases local bradykinin production and activates protease-activated receptor-2 (PAR-2) on endothelial cells and immune cells, perpetuating inflammation and vasodilation. Additionally, commensal Demodex mites (particularly Demodex folliculorum) are present in increased numbers in rosacea-affected skin. While not a primary cause, these mites can trigger or exacerbate rosacea through TLR activation and enhanced innate immune responses, leading to increased interest in antiparasitic and anti-inflammatory treatments targeting this organism.

• Vascular endothelial growth factor (VEGF) and angiogenesis: Increased VEGF expression in rosacea skin promotes angiogenesis and vascular proliferation, contributing to telangiectasia formation and persistent erythema. Hypoxia-inducible factor-1α (HIF-1α) activation in response to vascular dysfunction and chronic inflammation upregulates VEGF, perpetuating a cycle of abnormal neovascularization.

• Matrix metalloproteinase (MMP) dysregulation: Elevated MMP-2 and MMP-9 activity degrades collagen and extracellular matrix, contributing to skin atrophy and loss of structural integrity. This process is exacerbated by oxidative stress and chronic inflammation, explaining the progressive nature of disease and potential for development of phymatous changes.

• Reactive oxygen species (ROS) and oxidative stress: Increased oxidative stress in rosacea skin, with elevated ROS production and impaired antioxidant defense mechanisms, perpetuates vascular dysfunction and inflammatory cascade activation. UV radiation, heat, and inflammatory mediators all contribute to ROS generation, creating a feed-forward inflammatory loop.

• Genetic predisposition: Strong familial clustering and ethnic predilection (Northern European, Celtic ancestry) suggests genetic susceptibility. Genome-wide association studies have identified polymorphisms in genes regulating innate immunity, vascular function, and barrier integrity. Relatives of affected individuals have approximately 3-fold increased risk, though inheritance pattern is polygenic and incompletely penetrant. No single Mendelian inheritance pattern exists; instead, multiple common variants of small effect size cumulatively increase risk.

• Environmental triggers: Numerous environmental factors precipitate or exacerbate rosacea in genetically predisposed individuals:
• Thermal triggers: Hot beverages, hot weather, sauna/steam exposure, and strenuous exercise increase facial blood flow and trigger flushing
• Spicy foods and alcohol: Capsaicin in spicy foods and alcohol (especially red wine and spirits) cause vasodilation; alcohol additionally may increase local vasodilatory neuropeptide release
• Emotional stress: Anxiety, embarrassment, and anger trigger neurogenic inflammation through central sympathetic activation and local neuropeptide release
• UV radiation: Chronic photodamage exacerbates vascular dysfunction, oxidative stress, and innate immune activation
• Topical irritants: Harsh skincare products, astringents, and certain medications irritate sensitive rosacea-prone skin

• Demodex mite colonization: While presence of Demodex mites alone is not causative (commensal in healthy skin), increased density and altered immune response to these organisms may perpetuate inflammation in susceptible individuals. Antiparasitic treatment efficacy supports this hypothesis.

• Vascular and neurogenic abnormalities: Inherent abnormalities in cutaneous vasculature and trigeminal nerve signaling appear to be primary predisposing factors, though specific genetic/molecular basis remains incompletely characterized.

• Helicobacter pylori infection: Earlier associations with H. pylori have been largely refuted by subsequent large-scale studies; current evidence does not support H. pylori as a significant etiology in most populations.

• Flushing and transient erythema: The hallmark early feature, characterized by recurrent episodes of facial warmth, redness, and burning sensation, typically triggered by identifiable factors (thermal, dietary, emotional, environmental). Flushing episodes are physiologically driven by abnormal vasodilation and last minutes to hours. This symptom often precedes development of persistent erythema and vascular changes by months to years.

• Persistent facial erythema: Progressive central facial redness involving the cheeks, nose, chin, and forehead, reflecting chronic vasodilation and vascular proliferation. This erythema becomes increasingly fixed and less dependent on specific triggers as disease advances. The distribution characteristically spares the periocular area initially and the posterior neck.

• Telangiectasia: Visibly dilated small vessels (capillaries and small arterioles) appearing as fine linear or branching red lines on the face, reflecting chronic structural vascular changes. These result from cumulative vasodilatory episodes and loss of vascular wall integrity due to MMP activity and chronic inflammation. Telangiectasia may progress and become the predominant clinical feature in advanced disease.

• Papules and pustules: Inflammatory papules and pustules resembling acne occur in the erythematous areas, particularly affecting the central face. Unlike acne, rosacea pustules and papules are typically smaller, more uniform in size, do NOT contain comedones (distinguishing from acne vulgaris), and persist despite appropriate anti-acne therapy. Follicular distribution may occur but comedones are notably absent. The presence of pustules without comedones is a key distinguishing feature from acne.

• Burning and stinging sensation: Significant sensory symptoms including burning, stinging, pain, and pruritus are common and often precede visible skin changes. This burning sensation is mediated by neurogenic inflammation and trigeminal nerve sensitization and may be out of proportion to objective skin findings, sometimes leading to initial misdiagnosis as atopic dermatitis or contact dermatitis. Symptom severity correlates imperfectly with objective erythema extent.

• Ocular involvement (rosacea keratitis): Approximately 50% of rosacea patients develop ocular symptoms including dry eyes (xerophthalmia), grittiness, photophobia, foreign body sensation, and tearing. Meibomian gland dysfunction with lipid layer abnormalities occurs frequently. In more severe disease, anterior blepharitis, conjunctival injection, marginal keratitis, or rarely, severe keratitis with corneal neovascularization may develop. Ocular involvement often correlates with cutaneous severity but may occur independently.

• Phymatous changes (rhinophyma): Late-stage disease characterized by thickened, enlarged, irregular facies with prominent nodules and sebaceous gland hypertrophy, most commonly affecting the nose (rhinophyma) but potentially involving the chin (gnathophyma), ears (otophyma), or eyelids (blepharophyma). These changes reflect chronic sebaceous gland hypertrophy, fibrosis, and dermal thickening. Phymatous changes are more common in men and represent end-stage disease that rarely improves significantly with medical therapy alone, potentially requiring surgical intervention (laser, dermabrasion).

• Subtype classification:
• Subtype 1 (erythematotelangiectatic): Flushing, persistent erythema, and telangiectasia predominate without papular/pustular lesions
• Subtype 2 (papulopustular): Persistent erythema with inflammatory papules/pustules, may resemble acne
• Subtype 3 (phymatous): Skin thickening with nodules and coarse enlarged pores, primarily nose
• Subtype 4 (ocular): Ocular manifestations as primary feature

• Major diagnostic criteria (one major criterion is sufficient for diagnosis):
• Persistent facial erythema (central face: cheeks, nose, chin, forehead)
• Transient flushing triggered by identifiable triggers
• Papules and pustules WITHOUT comedones
• Telangiectasia

• Minor diagnostic criteria (support diagnosis when major criteria present):
• Burning or stinging sensation
• Edema
• Dry appearance
• Plaques
• Ocular involvement

• Clinical assessment approach:
• History: Detailed characterization of triggers (thermal, dietary, emotional, environmental), symptom onset and progression, impact on quality of life, past treatments, family history. Key historical features include rosacea "flare factors" (heat, spicy foods, alcohol, stress, UV exposure, irritating topicals). Absence of comedones in pustular lesions should be specifically noted.
• Physical examination: Careful morphologic assessment of distribution (central face with characteristic sparing of chin in early disease), character of erythema (persistent vs transient), presence/absence of comedones, assessment for telangiectasia, papules, pustules, skin texture changes, and phymatous features. Examination in warm room may provoke flushing response. Ocular examination including assessment of lid margin, meibomian glands, and any corneal involvement is important.
• Diagnostic scoring systems: The Rosacea Severity Index (RSI) and Clinician's Erythema Assessment (CEA) scale provide standardized approaches to severity assessment and are useful for monitoring treatment response over time. The Standard Classification System categorizes disease into subtypes and grades severity.

• Laboratory and imaging: No specific laboratory test diagnoses rosacea. Skin biopsy is rarely needed but may show perivascular lymphocytic infiltrate, dilated capillaries, and absence of follicular involvement, which can support diagnosis if clinical picture is atypical. Dermoscopy may reveal dilated vessels and absence of comedones, supporting distinction from acne. Laboratory studies (CBC, comprehensive metabolic panel, antinuclear antibody) are not routinely indicated unless clinical picture suggests alternative diagnosis.

• Differential diagnosis considerations:
• Acne vulgaris: Presents with comedones (absent in rosacea), affects younger patients, distribution typically includes forehead; rosacea characteristically lacks comedones despite pustular appearance
• Seborrheic dermatitis: Erythema and scaling more pronounced, perinasal and parting-line distribution, responds to antifungals; rosacea more symmetric and central distribution
• Systemic lupus erythematosus (SLE): Classic malar "butterfly" rash, but systemic manifestations, positive ANA, constitutional symptoms distinguish SLE; rosacea lacks systemic features and serologic abnormalities
• Polymorphous light eruption: Seasonally dependent, affects sun-exposed areas beyond face, histology shows lymphocytic infiltrate with dermal-epidermal junction involvement
• Contact dermatitis: History of exposure, involves exposed areas beyond face, eczematous appearance with scale and lichenification
• Melasma: Symmetric hyperpigmentation without significant erythema, telangiectasia, or papules; different ethnic distribution pattern

• First-line pharmacologic treatment—Topical agents:
• Metronidazole 0.75-1% (gel, cream, lotion, once or twice daily): Remains gold-standard first-line topical agent despite uncertain mechanism of action; likely combines antiparasitic properties (against Demodex), anti-inflammatory effects, and antimicrobial properties. Onset of action typically 2-3 weeks, full effect at 2-3 months. Sensory symptoms often improve before visible skin changes. Well-tolerated with minimal systemic absorption.
• Azelaic acid 15-20% (gel, foam, once or twice daily): Effective alternative with antimicrobial and anti-inflammatory properties, potent against Demodex. May be superior to metronidazole for papulopustular disease. Generally well-tolerated, though initial stinging occurs in 10-15% of patients; onset similar to metronidazole (2-3 weeks). Particularly useful in darker-skinned patients due to lack of hyperpigmentation risk (unlike some treatments).
• Sulfacetamide-sulfur preparations (10%-5% lotion/cleanser, once or twice daily): Older agent with antimicrobial and keratolytic properties. Onset 1-2 weeks. Less commonly used as first-line due to odor and staining potential, though still effective. Useful alternative in patients with intolerance to other agents.
• Ivermectin 1% (cream, once daily evening): Newer topical agent with anti-inflammatory and antiparasitic properties against Demodex. Rapidly emerging as preferred first-line agent with clinical improvement noted within 2 weeks and maximal benefit at 8-12 weeks. Superior efficacy compared to metronidazole in some studies. Well-tolerated with minimal irritation. Increasingly recommended as initial topical therapy.

• Systemic therapy for moderate-to-severe disease:
• Oral antibiotics—Low-dose doxycycline (40-100 mg daily for 8-12+ weeks): Doxycycline at subantimicrobial doses (40 mg = modified-release formulation) provides anti-inflammatory effects independent of antimicrobial activity by inhibiting MMPs and reducing inflammatory mediator production. Standard doses (50-100 mg once or twice daily) are effective but higher doses provide no additional benefit over subantimicrobial doses. Onset of action 4-6 weeks, plateau effect at 8-12 weeks. Generally well-tolerated but photosensitivity risk requires sun protection counseling. Contraindicated in pregnancy (teratogenic), children <8 years (risk of teeth staining), and those with severe hepatic/renal disease.
• Alternative oral antibiotics (if doxycycline intolerant/contraind

Disease-related complications

• Ocular rosacea progressing to keratitis: Meibomian gland dysfunction and lid-margin inflammation destabilize the tear film; chronic exposure and inflammatory neovascularization can produce marginal corneal infiltrates, ulceration, and rarely perforation. Pain, photophobia, or decreased visual acuity is an emergency — same-day ophthalmology evaluation, consistent with the American Academy of Ophthalmology Blepharitis Preferred Practice Pattern. Ocular disease may precede skin findings and does not track reliably with cutaneous severity.
• Rhinophyma and other phymas: Sebaceous hyperplasia and dermal fibrosis produce irreversible disfigurement and, when bulky, nasal airway obstruction. An asymmetric, ulcerated, or rapidly enlarging nodule within a phyma should be biopsied — basal cell carcinoma and rarely angiosarcoma hide in phymatous tissue.
• **Solid persistent facial edema (Morbihan disease)**: Chronic lymphatic obstruction from repeated inflammation causes woody, non-pitting midface and eyelid swelling that responds poorly to standard therapy.
• Psychiatric morbidity: Visible central facial disease carries well-documented rates of depression, anxiety, and social avoidance; screening is appropriate at follow-up.

Treatment-related complications

• Topical corticosteroids: The single most common iatrogenic harm. Initial vasoconstriction is followed by rebound erythema, telangiectasia, and steroid-induced rosacea/perioral dermatitis; withdrawal transiently worsens disease. Corticosteroids are not rosacea therapy.
• Topical alpha-adrenergic agonists (brimonidine, oxymetazoline): Vasoconstriction can be followed by paradoxical worsening erythema or rebound flushing after wear-off, a labeled adverse effect.
• Doxycycline: Photosensitivity (compounding UV as a trigger), pill esophagitis, Clostridioides difficile colitis, and drug-induced intracranial hypertension — new headache with visual obscurations or papilledema warrants urgent evaluation and drug discontinuation. Contraindicated in pregnancy and children under 8.
• Isotretinoin: Reserved for refractory or phymatous disease; teratogenicity mandates iPLEDGE enrollment with two contraception methods and serial pregnancy testing, plus monitoring for hypertriglyceridemia and transaminitis.
• Laser/light and surgical phyma reduction: Purpura, dyspigmentation (higher risk in darker skin phototypes), and scarring.

• No comedones: Papules and pustules without comedones is the discriminator from acne vulgaris. The stem that says "open and closed comedones" is testing acne, not rosacea.
• Nasolabial folds: Rosacea erythema involves the nasolabial folds and central face; the malar butterfly rash of SLE classically spares them and comes with systemic features and a positive ANA. This is the most frequently tested distractor pair.
• Best next step in a patient on topical steroids: Stop the corticosteroid. Chronic facial steroid use causes steroid-induced rosacea, and the initial post-withdrawal flare is expected, not treatment failure.
• Eye complaints change management: Gritty, burning, photophobic eyes in a rosacea patient mean ocular rosacea — lid hygiene, warm compresses, artificial tears, and oral tetracycline-class therapy; pain or vision loss means urgent ophthalmology referral per the American Academy of Ophthalmology blepharitis Preferred Practice Pattern, because marginal keratitis can ulcerate.
• First-line pharmacotherapy is topical: Metronidazole, azelaic acid, or ivermectin, with photoprotection and trigger avoidance for every patient (American Academy of Dermatology and National Rosacea Society/ROSCO guidance). Escalate to subantimicrobial-dose doxycycline for papulopustular disease — its benefit is anti-inflammatory (MMP inhibition), so higher antibiotic doses add toxicity, not efficacy.
• Fixed lesions need fixed treatments: Telangiectasia and background erythema do not respond to antibiotics — vascular laser or intense pulsed light is the answer. Rhinophyma is fibrotic end-stage disease treated with ablative laser, electrosurgery, or surgical debulking, not with metronidazole.
• The association examiners test: Demodex folliculorum overgrowth with innate immune activation (elevated cathelicidin/kallikrein-5), which is why topical ivermectin works. Helicobacter pylori is a legacy association that current evidence does not support.
• Flushing red flags: Episodic flushing with diarrhea and wheezing suggests carcinoid; with headache, palpitations, and hypertension suggests pheochromocytoma; with urticaria pigmentosa and syncope suggests mastocytosis. Rosacea flushing has no systemic accompaniments.